{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:18:07Z","timestamp":1783675087068,"version":"3.55.0"},"reference-count":0,"publisher":"Bioscientifica","issue":"2","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1964,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Preliminary trials have been conducted, at the Royal Samaritan Hospital for Women, Glasgow, during the past 18 months with Pentovis (3-cyclopentyloxy-oestra-1:3:5(10)-triene-16\u03b1:17\u03b2-diol), a new synthetic oral oestrogen.<\/jats:p>\n                  <jats:p>Oestrogens should not be prescribed without consideration, since unpleasant sideeffects are not uncommon. Nausea, vomiting, and general malaise are the commonest, but uterine bleeding may be alarming and a source of confusion. Moreover, it has been suggested that uninterrupted oestrogen therapy, for a long period of time, may cause malignant disease of the genital tract. There is no good evidence, however, to prove that oestrogens are carcinogenic in women.<\/jats:p>\n                  <jats:p>Ercoli, Pellegrini &amp; Falconi (1961) have claimed that 'Colpovis' (known as 'Pentovis' in the U.K.) is more active than oestriol, its steroid parent compound. They also state that Colpovis exerts its effect selectively on the lower segments of the genital tract (cervix uteri, vagina and external genitalia), but influences the endometrium only slightly. It is<\/jats:p>","DOI":"10.1677\/joe.0.0290209","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T16:43:33Z","timestamp":1229013813000},"page":"209-210","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-5","source":"Crossref","is-referenced-by-count":2,"title":["A NEW SYNTHETIC ORAL OESTROGEN"],"prefix":"10.1530","volume":"29","author":[{"given":"A.","family":"SHARMAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","container-title":["Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/joe.bioscientifica.com\/view\/journals\/joe\/29\/2\/joe_29_2_015.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/joe\/article-pdf\/29\/2\/209\/52489\/joe_29_2_015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/joe\/article-pdf\/29\/2\/209\/52489\/joe_29_2_015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:49:23Z","timestamp":1783673363000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/joe\/article\/29\/2\/209\/7796\/A-NEW-SYNTHETIC-ORAL-OESTROGEN"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1964,5,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1964,5,1]]}},"URL":"https:\/\/doi.org\/10.1677\/joe.0.0290209","relation":{},"ISSN":["1479-6805","0022-0795"],"issn-type":[{"value":"1479-6805","type":"electronic"},{"value":"0022-0795","type":"print"}],"subject":[],"published":{"date-parts":[[1964,5,1]]}}}